Photosensitizers for blood vessel therapeutic targeting in laser radiation therapy
A COHb-based photosensitizer encapsulated in liposomes or polymersomes addresses the inefficiency of existing laser therapies by enhancing laser light absorption in blood vessels, improving treatment efficacy and reducing tissue damage.
Patent Information
- Application Number
- JP2020206156
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-12-11
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-12-11
AI Technical Summary
Existing laser irradiation therapies for treating blood vessel-related conditions, such as simple hemangioma, are inefficient as they require multiple treatments and often cause damage to surrounding tissues due to low absorption of laser light by blood vessels and high absorption by surrounding tissues.
A photosensitizer containing COHb (carbon monoxide-bound hemoglobin) is developed, encapsulated in liposomes or polymersomes, which is administered intravascularly to enhance laser light absorption by blood vessels, reducing thermal effects on surrounding tissues.
The photosensitizer enhances the therapeutic effect of laser irradiation by increasing laser light absorption in blood vessels, leading to more effective treatment of conditions like simple hemangioma with fewer side effects on surrounding tissues.
Smart Images

Figure 0007593592000010 
Figure 0007593592000011 
Figure 0007593592000012
Abstract
Description
[Technical field]
[0001] The present invention relates to a photosensitizer for laser radiation therapy, and more particularly to a photosensitizer for laser radiation therapy that targets blood vessels for treatment. [Background technology]
[0002] Laser irradiation therapy targeting capillaries as a therapeutic target was proposed in 1983 (Non-Patent Document 1). The principle of the therapy is as follows. A laser irradiation device capable of irradiating light with the absorption wavelength of oxyhemoglobin for a short period of time is prepared. Photons irradiated from a laser light source are absorbed by red blood cell oxyhemoglobin in the capillaries and converted into thermal energy. The thermal energy destroys the endothelial cells of the vascular wall, and the capillaries are eventually necrotized and absorbed, and disappear. Since the thermal energy remains within the blood vessels, there is little damage caused by thermal effects on the tissues surrounding the capillaries. Based on the relationship between the light absorption rate of hemoglobin and the absorption rate of water, collagen, and melanin in the skin, which may be other therapeutic targets, and the depth of penetration of the light into the skin, a pulsed dye laser (hereinafter referred to as "PDL") with a wavelength of 577 nm, 585 nm, or 595 nm has been used to treat simple hemangiomas. With the progress of optical technology, improvements have been made to laser irradiation devices, such as widening the pulse width of laser irradiation, increasing the frequency of subpulses, enlarging the diameter of the irradiation handpiece, and increasing the power of the laser device. For vascular lesions deep in the skin, some facilities use light with a long wavelength of 1064 nm for treatment, and irradiate lasers with wavelengths changed according to the condition of the affected skin. There have also been attempts to use photodynamic therapy, which combines a dye compound that produces active oxygen that reacts to light with a wavelength of 630 nm or 664 nm and damages tissues, with a laser light irradiation device with the above wavelengths, for the treatment of simple hemangiomas. As described above, various improvements have been made to laser irradiation therapy, including capillary PDL, but there has been no significant progress in the results of clearance (bringing the affected area closer to healthy skin without scarring) for the past 30 years or so (Non-Patent Document 2).
[0003] Simple hemangioma or capillary malformation is a flat red spot caused by the expansion of cutaneous capillaries. It is seen in 0.3% of newborns and is a common pigmented skin lesion in newborns. By simple calculation, as many as 300,000 patients develop this condition in Japan annually. Laser irradiation therapy is performed with the goal of making the affected area close to healthy skin without scarring (clearance), but multiple treatments are necessary to achieve a certain level of effect. The inventor of the present invention summarized the treatment results of 708 cases he himself experienced, and found that 69% of the cases were treated twice or less, 20% were treated three to five times, and 11% were treatment-resistant cases that were treated six or more times. This does not contradict the description in Non-Patent Document 3, which states that about 5 to 20% of lesions are treatment-resistant. Specifically, assuming that light with a wavelength of 590 nm is irradiated to the skin, a simulation was performed in which 1 million photons were irradiated to a skin model, and approximately 56% was absorbed by the living body, approximately 47% was absorbed by melanin and the dermis, and approximately 9% was absorbed by the blood vessels. Approximately 56% of the laser light energy irradiated to the affected area is absorbed by the body, but most of it is absorbed by the tissue surrounding the blood vessels, with only approximately 9% of the laser light energy irradiated to the affected area being absorbed by the blood vessels. In order to completely remove simple hemangiomas without leaving any aftereffects of burns on the tissue surrounding the blood vessels, it is necessary to develop a photosensitizer that can increase the proportion of laser light energy absorbed by the blood vessels and reduce burns to the tissue surrounding the blood vessels.
[0004] Encapsulated hemoglobin is a particle with a diameter of several hundred nm that encapsulates a highly concentrated aqueous solution of purified hemoglobin at 10-50 g / dL (1.6 mL-7.6 mM). Among the encapsulated hemoglobin, particles in which hemoglobin is encapsulated in liposomes are called hemoglobin vesicles. Hemoglobin vesicles that can be stored for a long time are manufactured through processes such as encapsulating an aqueous solution of hemoglobin in liposomes, removing hemoglobin that is not encapsulated, removing CO2 by photoreaction, and deoxygenation. Hemoglobin vesicles have the advantage that blood group substances and sources of infection are completely removed during the hemoglobin purification process, and they can be stored for a long time, making them usable immediately in an emergency. In addition, particles (hereinafter referred to as "COHb-V") in which carboxyhemoglobin (hereinafter referred to as "COHb"), in which CO (carbon monoxide) is bound to hemoglobin, is encapsulated in liposomes, gradually release CO for several hours after administration into the circulating blood, resulting in vasodilatory and anti-inflammatory effects, and also functions as an oxygen carrier after the release of CO (Non-Patent Document 4). [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Anderson RR and Parrish JA, Science, 220:524-527 (1983). [Non-Patent Document 2] van Raath MI et al., J. Eur. Acad. Dermatol. Venereol., 33:1369-77(2019) [Non-Patent Document 3] Ting, PT and Rao, J., Vascular Lesions, in Basics in Dermatological Laser Applications (I. Bogdan Allemann and DJ Goldberg ed., Current Problems in Dermatology, Vol. 42 (2011)) [Non-Patent Document 4] Sakai H., J. Funct. Biomater., 8:10(2017) Summary of the Invention [Problem to be solved by the invention]
[0006] An object of the present invention is to provide a novel photosensitizer for enhancing the therapeutic effect of laser irradiation therapy targeting blood vessels. [Means for solving the problem]
[0007] The present invention provides a photosensitizer for laser radiation therapy that contains COHb and targets blood vessels for therapy.
[0008] The photosensitizer of the present invention can contain the COHb in the form of encapsulated hemoglobin (hereinafter referred to as "COHb-C") in which an aqueous COHb solution is encapsulated in a capsule.
[0009] In the photosensitizer of the present invention, the aqueous solution may contain pyridoxal 5'-phosphate (hereinafter referred to as "PLP").
[0010] The photosensitizers of the present invention may be substantially devoid of enzymatic activity to reduce methemoglobin.
[0011] In the photosensitizer of the present invention, the aqueous solution may contain NADH and / or NADPH.
[0012] In the photosensitizer of the present invention, the aqueous solution may contain a biodegradable fluorescent dye.
[0013] In the photosensitizer of the present invention, the hemoglobin concentration in the aqueous solution can be 1.6 mM to 7.0 mM (10 g / dL to 45 g / dL).
[0014] In the photosensitizer of the present invention, the capsule may be a liposome, a polymersome or a thin polymer film.
[0015] In the photosensitizer of the present invention, the liposome contains 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine, which is a phosphatidylcholine-type phospholipid, cholesterol, 1,5-O-dihexadecyl-N-succinyl-glutamate, which is a negatively charged lipid, and 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-poly(oxyethylene) 5000 (polyethylene glycol chain molecular weight 5000).
[0016] The photosensitizer of the present invention can contain the COHb as an aqueous solution of an acellular hemoglobin-derived oxygen carrier (Hb-based O2 carrier) bound to CO. The acellular hemoglobin-derived oxygen carrier can be at least one selected from the group consisting of polymerized modified hemoglobin, water-soluble polymer-bound modified hemoglobin, and intramolecularly crosslinked hemoglobin.
[0017] In the photosensitizer of the present invention, the non-cellular hemoglobin-derived oxygen carrier may be a polymerized modified hemoglobin and / or a water-soluble polymer-bound modified hemoglobin.
[0018] The photosensitizer of the present invention can be administered at a hemoglobin concentration of 0.46 mM to 3.6 mM (3 g / dL to 23 g / dL).
[0019] The photosensitizer of the present invention can be administered at 0.004 mmol to 0.36 mmol of carbon monoxide per kg of body weight.
[0020] The photosensitizer of the present invention may be used for the treatment of at least one disease selected from the group consisting of simple hemangioma, capillary malformation, salmon patch, Unna's nevus, hemangioma, port wine stain, Sturgey-Weber syndrome, Klippel-Trenaunay-Weber syndrome and other skin lesions caused by capillary hyperplasia, rosacea and telangiectasia, pathological vascular dilation associated with hypertrophic scars, traumatic scars and post-skin graft scars, strawberry hemangioma and infantile hemangioma of the skin, and tufted hemangioma, telangiectatic granuloma and other vascular neoplastic lesions of the skin.
[0021] The present invention provides a laser irradiation therapy targeting blood vessels as a therapeutic target, which comprises a step of administering the photosensitizer of the present invention and then irradiating with a laser.
[0022] The laser irradiation therapy of the present invention may be used to treat at least one disease selected from the group consisting of simple hemangiomas, capillary malformations, salmon patches, Unna's nevus, hemangiomas, port wine stains, Sturgey-Weber syndrome, Klippel-Trenaunay-Weber syndrome and other skin lesions caused by capillary hyperplasia, rosacea and telangiectasias, pathological vascular dilation associated with hypertrophic scars, traumatic scars and post-skin graft scars, strawberry hemangiomas and infantile hemangiomas of the skin, and tufted hemangiomas, telangiectatic granulomas and other vascular neoplastic lesions of the skin.
[0023] The present invention provides a use for the production of a photosensitizer for laser radiation therapy that targets the blood vessels of COHb as a therapeutic target.
[0024] In the use for producing a photosensitizer for laser irradiation therapy targeting blood vessels according to the present invention, the COHb can be COHb-C. Alternatively, in the use for producing a photosensitizer for laser irradiation therapy targeting blood vessels according to the present invention, the photosensitizer can contain the COHb as an aqueous solution of a noncellular hemoglobin-derived oxygen carrier bound to CO, in which CO is bound to at least one noncellular hemoglobin-derived oxygen carrier selected from the group consisting of polymerized modified hemoglobin, water-soluble polymer-bound modified hemoglobin, and intramolecularly crosslinked hemoglobin.
[0025] The use of the present invention for the manufacture of a photosensitizer for laser irradiation therapy targeting blood vessels as a therapeutic target can be used for the manufacture of the photosensitizer for the treatment of at least one disease selected from the group consisting of simple hemangioma, capillary malformation, salmon patch, Unna's nevus, hemangioma, port wine stain, Sturgey-Weber syndrome, Klippel-Trenaunay-Weber syndrome, and other skin lesions caused by capillary hyperplasia, rosacea and telangiectasia, pathological vascular dilation associated with hypertrophic scars, traumatic scars, and post-skin graft scars, strawberry hemangioma and infantile hemangioma of the skin, and tufted hemangioma, telangiectatic granuloma, and other vascular tumor lesions of the skin. [Brief description of the drawings]
[0026] [Figure 1-A] A photograph of the external surface of the ear skin at irradiation site 1 four days after a rabbit ear was administered completely deoxygenated hemoglobin vesicles (hereinafter referred to as "Hb-V" in the brief description of the drawings and in the examples) and was irradiated with a dye laser. [Figure 1-B] Photograph of the external surface of the ear skin at irradiation site 1 4 days after dye laser irradiation on the ear of a rabbit administered COHb-V. [Figure 2-A] A photograph of the external surface of the ear skin at irradiation site 2, 4 days after dye laser irradiation of the ear of a rabbit administered Hb-V. [Figure 2-B] Photograph of the external surface of the ear skin at irradiation site 2, 4 days after dye laser irradiation on the ear of a rabbit administered COHb-V. [Figure 3-A]A photograph of the external surface of the ear skin at irradiation site 3, 4 days after dye laser irradiation on the ear of a rabbit administered Hb-V. [Figure 3-B] Photograph of the external surface of the ear skin at irradiation site 3, 4 days after dye laser irradiation of the ear of a rabbit administered COHb-V. [Figure 4-A] A photograph of the external surface of the ear skin at irradiation site 4, 4 days after dye laser irradiation of the ear of a rabbit administered Hb-V. [Figure 4-B] Photograph of the external surface of the ear skin at irradiation site 3, 4 days after dye laser irradiation of the ear of a rabbit administered COHb-V. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0027] One embodiment of the present invention is a photosensitizer for laser therapy that contains COHb and therapeutically targets blood vessels.
[0028] Laser irradiation therapy targeting blood vessels as therapeutic targets was proposed by Anderson RR and Parrish JA (Non-Patent Document 1). This is a treatment method in which capillaries or melanomas are irradiated with laser light under set conditions such as appropriate wavelength, intensity, and irradiation time, and the thermal energy is concentrated only on the capillaries or melanoma, thereby removing the capillaries or melanoma without affecting the surrounding tissue. In the case of capillaries, the laser light is irradiated with oxyhemoglobin (hereinafter referred to as "O2Hb"). The laser light is absorbed by the O2Hb in red blood cells in the blood vessels and converted into thermal energy. This thermal energy is transmitted to the blood vessel wall, destroying the vascular endothelium, and finally the abnormal blood vessels are necrotic and absorbed. Since the thermal energy remains within the blood vessels, it rarely causes thermal damage to the tissues surrounding the blood vessels. Based on the relationship between the light absorption rate of O2Hb and the absorption rate of other potential targets in the skin, such as water, collagen, and melanin, as well as the depth to which the light penetrates the skin, lasers with wavelengths of 577 nm, 585 nm, 595 nm, or 1064 nm are used for laser irradiation therapy targeting blood vessels.
[0029] The flow velocity of blood near the vessel wall is slower than that in the center of the vessel. Because the shear stress of the flow is large near the wall, red blood cells move toward the center of the vessel while deforming, and flow through the center of the vessel. As a result, a plasma layer without red blood cells is formed near the inner wall of the vessel. This is called the "cell free layer" or "endothelial surface layer" (Kim, S. et al., Biorheology 46: 181-189 (2009)). Encapsulated hemoglobin and / or noncellular hemoglobin-derived oxygen carriers (including polymerized modified hemoglobin, water-soluble polymer-bound modified hemoglobin, and intramolecularly cross-linked hemoglobin) are smaller in size than red blood cells, and therefore can flow through the cell free layer near the vessel wall, unlike red blood cells. In capillaries, plasma flows continuously through the lumen, but red blood cells do not flow continuously, but flow intermittently while deforming their shape. In contrast, encapsulated hemoglobin can flow continuously in the capillaries along with the plasma flow (Hyakutake, T. et al., J Biomech Eng., 130: 011014 (2008)). The non-cellular hemoglobin-derived oxygen carrier can flow continuously in the capillaries together with the plasma in a state dissolved or suspended in the plasma. In this way, intravascular administration of encapsulated hemoglobin and / or non-cellular hemoglobin-derived oxygen carrier has the effect of homogenizing the naturally occurring hemoglobin concentration distribution in the cross section of the blood vessel, and makes it possible to place hemoglobin (light absorber and heat generator) that absorbs laser light and converts it into heat near the vascular endothelium. The light absorber / heat generator and the blood vessel wall are closer than ever before, and heat is efficiently transmitted to the blood vessel wall. This is advantageous for laser irradiation therapy that targets the blood vessel wall as a treatment target.
[0030] Light sources used in laser irradiation therapy targeting blood vessels include 577, 585 or 595 nm PDL, 755 nm Alexandrite laser, 810 nm diode laser and 1064 nm long pulse Nd:YAG laser. The distance from the skin surface that the light energy reaches varies depending on the type of laser, and PDL is most preferable for treatment targeting capillaries shallow from the skin surface. However, light sources other than PDL are also options for laser irradiation therapy targeting blood vessels (Non-Patent Document 3).
[0031] The photosensitizer for laser irradiation therapy targeting blood vessels according to the present invention is used to enhance the effect of laser irradiation therapy targeting blood vessels. The photosensitizer of the present invention is administered into blood vessels by injection into a vein or an artery. When the photosensitizer of the present invention is administered into a vein, the photosensitizer administered into a vein reaches the capillaries of the treatment target via the heart and artery, so a large amount of the photosensitizer needs to be administered. This amount reaches 5% to 20% of the circulating blood volume. The circulating blood volume is about 1 / 13 of the patient's body weight, so for example, for a child weighing 20 kg, the circulating blood volume is about 1.5 kg, or about 1.5 L. Therefore, 5% to 20% of the circulating blood volume corresponds to about 77 mL to 307 mL. When the photosensitizer of the present invention is administered into an artery upstream of the capillaries of the treatment target, a smaller amount of photosensitizer than that administered intravenously can be used to achieve a therapeutically effective local concentration.
[0032] A method for preparing hemoglobin for use in the photosensitizer for laser treatment of the present invention is described in Sakai H. et al. (Methods Enzymol. 465:363-84 (2009)) and International Publication No. WO2012 / 137834.
[0033] Briefly, the hemoglobin used in the photosensitizer for laser treatment of the present invention is purified and concentrated from blood derived from humans or livestock. Alternatively, hemoglobin produced by microorganisms using genetic recombination technology is purified and concentrated. The purification and concentration may be performed, for example, according to the following procedure, but is not limited to this procedure and may be performed by any procedure known to those skilled in the art. First, blood derived from humans or livestock is centrifuged to remove the supernatant plasma components and buffy coat, an isotonic solution (saline or phosphate buffered saline) is added and gently stirred, and then centrifuged again to remove the supernatant. This procedure is repeated three times to obtain washed red blood cells. When a hypotonic solution (such as pure water) is added, the red blood cells are hemolyzed and hemoglobin is released. Membrane components are precipitated and removed by ultracentrifugation, or only hemoglobin is passed through an ultrafiltration membrane (molecular weight cutoff of about 1,000,000) to remove the membrane components.
[0034] In preparing hemoglobin for use in the photosensitizer for laser therapy of the present invention, hemoglobin is purified and concentrated from blood derived from humans or livestock, and then heat treatment for virus inactivation and / or nanofiltration treatment for virus removal are performed. Heat treatment for virus inactivation may be performed, for example, by heating the purified and concentrated hemoglobin solution at 60°C for 10 to 12 hours. In order to make hemoglobin heat-resistant, the purified and concentrated hemoglobin solution is transferred to a heat-resistant sealed container before the heat treatment, and the solution is repeatedly filled with carbon monoxide gas and stirred to replace O2Hb with COHb. Nanofiltration treatment for virus removal may be performed, for example, by filtering the purified and concentrated hemoglobin solution that has been subjected to heat treatment for virus inactivation through a nanofiltration membrane with a pore size of 15 to 50 nm.
[0035] By the operation of heat treatment and nanofiltration, the total inactivation rate and removal rate (Log Reduction Value) exceeds 9, which meets the requirements for virus clearance validation. By these operations, the glycolysis system, the methemoglobin reduction system, the decarboxylase, and the enzymes that eliminate active oxygen are all eliminated. In particular, it is well known that NADH-cytochrome b5 reductase, which uses NADH as a substrate, and cytochrome b5, which is an electron carrier, related to the present invention, have poor heat resistance (Arinc E. et al., Comp Biochem Physiol B. Jan-Feb;101(1-2):235-42. (1992)), and are denatured and inactivated during heat treatment. The protein purity of the hemoglobin solution becomes extremely high (99.8% or more) by heat treatment. In addition, even when the enzyme activity of NADH-cytochrome b5 reductase and NADPH-flavin reductase is measured, it is confirmed that there is no activity.
[0036] The COHb solution that has undergone the virus inactivation and removal steps is concentrated by ultrafiltration after undergoing dialysis, pH adjustment, etc. The molecular weight cutoff at this time is about 8,000 to 30,000, and can be efficiently performed. The obtained COHb solution has a concentrated Hb concentration of 30 to 45 g / dL. This solution is treated with an anion exchange resin and passed through a sterilized filter with a pore size of 0.22 μm.
[0037] One embodiment of the present invention is a photosensitizer for laser irradiation therapy targeting blood vessels, which comprises COHb as encapsulated hemoglobin (COHb-C) in which an aqueous COHb solution is encapsulated in a capsule.
[0038] In the photosensitizer for laser radiation therapy of the present invention, the capsule can be a liposome, a polymersome or a polymer thin film.
[0039] When the capsule is a liposome, the liposome can have various compositions (Sakai H. et al., Methods Enzymol. 2009;465:363-84.; Djordjevich, L. and Miller, IF, Fed. Proc., 36:567(1977)). When the capsule of the encapsulated hemoglobin is a liposome, the encapsulated hemoglobin is called a hemoglobin vesicle. In one example of a hemoglobin vesicle, the liposome is composed of 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), cholesterol, 1,5-O-dihexadecyl-N-succinyl-L-glutamate (DHSG), and 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-PEG. 5000 (DSPE-PEG 5000 ) consists of four components.
[0040] When the capsule is a polymersome, the polymersome is a capsule formed by an amphiphilic polymer in which a hydrophilic polymer and a hydrophobic polymer are copolymerized, for example, an amphiphilic diblock copolymer of polybutadiene-polyethylene oxide (PBD-PEO) (Arifin, DR and Palmer, AF, Biomacromolecules, 6:2172-81 (2005)).
[0041] When the capsule is a polymer thin film, the polymer thin film can be made of polymers including, but not limited to, polystyrene, gum arabic, nylon, silicone, and other polymers, biomaterials such as gelatin, copolymers of poly-ε-caprolactam or polyethylene glycol with biodegradable polymers such as polylactic acid or polyglycolic acid, polysaccharides, and copolymers of amino acid polymers (Chang TMS, Eur. J. Pharm. Biopharm. 45:3-8.(1998)).
[0042] Known methods for encapsulating hemoglobin include ultrasonic treatment (probe method, bath method), organic solvent injection method, surfactant removal method, freeze-thaw method, reverse phase evaporation method, extrusion method, dry lipid powder-hydration method, high pressure emulsification dispersion method, kneading method using planetary motion, etc. To encapsulate hemoglobin without denaturing it, the dry lipid powder-hydration method, extrusion method, kneading method, etc. are preferred.
[0043] In the photosensitizer for laser irradiation therapy of the present invention, the size of the COHb-C is required to be smaller than that of red blood cells so that it can disperse and flow in the plasma layer (cell free layer or endothelial surface layer) formed near the inner wall surface of a blood vessel. The average size of the COHb-C is about 50 nm to about 500 nm, or about 220 nm to about 280 nm, or about 250 nm to about 280 nm, or about 250 nm, as measured by dynamic light scattering.
[0044] Additives can be added to the COHb solution contained in COHb-C, including, but not limited to, PLP, NADH, and NADPH.
[0045] After the encapsulation step, hemoglobin that is not encapsulated in the capsules can be removed by filtration using an ultrafiltration membrane (e.g., molecular weight cutoff of 1000 kDa). Alternatively, the encapsulated hemoglobin can be precipitated by centrifugation, the supernatant hemoglobin solution can be removed, and physiological saline or the like can be added to the precipitate to redisperse the encapsulated hemoglobin. The solution in which the encapsulated hemoglobin is redispersed may contain electrolytes, carbohydrates, amino acids, and / or colloids, and additives such as those not limited to these can also be added.
[0046] When hemoglobin that does not bind CO is required, COHb can be converted to O2Hb by a photochemical reaction under oxygen flow. The reaction proceeds rapidly by forming a liquid membrane or by irradiating the hemoglobin with visible light while passing through a dialysis membrane (Patent Publication No. 3682072).
[0047] One embodiment of the present invention is a photosensitizer for laser irradiation therapy targeting blood vessels as a therapeutic target, wherein the aqueous hemoglobin solution contained in the encapsulated hemoglobin contains pyridoxal 5'-phosphate (PLP).
[0048] PLP, as an allosteric factor for adjusting the oxygen affinity of hemoglobin, can be added so that the molar ratio to hemoglobin is 0.5 to 3. Alternatively, when the molar concentrations of PLP and hemoglobin encapsulated in the artificial red blood cells of the present invention are represented as [PLP] and [Hb], respectively,
number
[0049] One embodiment of the present invention is a photosensitizer for laser radiation therapy that therapeutically targets blood vessels and is substantially free of enzymatic activity that reduces methemoglobin.
[0050] In this specification, the term "methemoglobin-reducing enzyme" includes, but is not limited to, NADH-based methemoglobin reductase, which uses nicotinamide adenine dinucleotide (NADH) as a substrate, and NADPH-based methemoglobin reductase. NADH-methemoglobin reductase has been reported as an NADH-based methemoglobin reductase, and it has been revealed that this mechanism involves the action of NADH-cytochrome b5 reductase and the reduction of metHb with cytochrome b5 as an electron medium. Oxidized NAD +is restored to NADH via the Embden-Myerhof pathway. NADH cytochrome b5 reductase exists in the red blood cell membrane and in solution in the red blood cell. The NADPH-based methemoglobin reductase reduces metHb by the action of NADPH methemoglobin reductase, which uses nicotinamide adenine dinucleotide phosphate (NADPH) as a substrate, and converts it to oxidized NADP + is restored to NADPH via the pentose phosphate pathway. + "Enzyme system capable of converting NADP to NADH" and "NADP + The enzymes that can convert methemoglobin to NADPH are glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in the Embden-Myerhof pathway, and glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH) in the pentose phosphate pathway. + and / or NADP + is a different enzyme from the "enzyme system capable of converting NADH to NADH and / or NADPH."
[0051] With respect to the enzyme that reduces methemoglobin in this specification, "substantially no enzyme activity" refers to an enzyme activity that is 10%, 5%, 3%, 1%, 0.5%, 0.2%, 0.1%, 0.05%, or 0.03% or less of the enzyme activity of a hemoglobin solution purified and concentrated from human or livestock blood, or is below the detection limit of the enzyme activity of methemoglobin reductase. Here, the enzyme activity of the enzyme that reduces methemoglobin in this specification can be determined, for example, by the following procedure.
[0052] The measurement of NADH-cytochrome b5 reductase activity can be carried out according to Beutler, E. (RED CELL MTABOLISM: A MANUAL OF BIOCHEMICAL METHOD, Grune & Stratton, Inc. pp.81-82(1987)). The measurement principle is that NADH methemoglobin reductase is measured as NADH-ferricyanide reductase activity in this method. [ka] The activity is measured by tracking the degree to which the reaction is promoted by the addition of a sample containing the enzyme. The change (decrease) in absorbance at 340 nm, the characteristic absorption of NADH consumed, is measured.
[0053] The NADPH-flavin reductase activity can be measured according to Beutler, E. (RED CELL MTABOLISM: A MANUAL OF BIOCHEMICAL METHOD, Grune & Stratton, Inc. pp. 79-80 (1987)). The measurement principle is that NADH methemoglobin reductase is measured as NADH diaphorase activity in this method. This is a reaction in which methylene blue (MB) is reduced to leukomethylene blue (LeukMB), [ka] Although it is known to be a slow reaction, activity is measured by tracking the degree to which it is accelerated by the addition of a sample containing the enzyme. Specifically, the change (decrease) in absorbance at 340 nm, characteristic absorption of NADPH consumed, is measured, and activity is determined based on the above principle.
[0054] The state in this specification where there is substantially no activity of the enzyme that reduces methemoglobin can be achieved by purifying and concentrating hemoglobin from blood derived from humans or livestock, followed by a heat treatment for virus inactivation and / or a nanofiltration treatment for virus removal.
[0055] One embodiment of the present invention is a photosensitizer for laser irradiation therapy targeting blood vessels as a therapeutic target, wherein the aqueous hemoglobin solution contained in the encapsulated hemoglobin contains NADH and / or NADPH.
[0056] The NADH and / or NADPH of the present invention are added in an amount of 0.5 to 10 in terms of molar ratio relative to the hemoglobin in the hemoglobin solution encapsulated in the encapsulated hemoglobin of the present invention. Alternatively, the NADH and / or NADPH are added in an amount of 1 to 3 in terms of molar ratio relative to the hemoglobin in the aqueous hemoglobin solution encapsulated in the encapsulated hemoglobin. When the molar concentrations of the NADH, NADPH, and hemoglobin encapsulated in the encapsulated hemoglobin are represented as [NADH], [NADPH], and [Hb], respectively,
number
number
[0057] In one embodiment of the present invention, the aqueous hemoglobin solution contains a biodegradable fluorescent dye and is a photosensitizer for laser radiation therapy targeting blood vessels.
[0058] The biodegradable fluorescent dye includes, but is not limited to, sodium fluorescein and other fluorescent contrast agents that have been clinically used in the past. It is desirable that the biodegradable fluorescent dye does not impair the effect of the dye laser treatment photosensitizer of the present invention in the treatment by laser irradiation therapy targeting the blood vessel of the present invention by laser irradiation with a wavelength of 577 to 595 nm. In this respect, sodium fluorescein has a maximum absorption wavelength of 494 nm, and at 550 nm, the absorbance at 488 nm is almost 0%, so the influence of the laser irradiation is difficult to imagine. The photosensitizer for laser treatment containing the biodegradable fluorescent dye has the advantage that the concentration of hemoglobin particles in the capillaries to be treated can be confirmed non-invasively in real time, and laser irradiation can be performed when the concentration is the highest. When sodium fluorescein, one of the biodegradable fluorescent dyes, is used as a fluorescent fundus contrast agent, the package insert states that 200 mg to 500 mg is administered from the cubital vein. Therefore, when the photosensitizer of the present invention is used at the dosage described below, it is preferable to incorporate the biodegradable fluorescent dye so that the total dosage administered to the patient contains a maximum of 200 mg to 500 mg.
[0059] One embodiment of the present invention is a photosensitizer for laser irradiation therapy targeting blood vessels as a therapeutic target, in which the hemoglobin concentration in an aqueous solution to be encapsulated in the encapsulated hemoglobin is 1.6 mM to 7.0 mM.
[0060] The concentration of the hemoglobin solution purified by first hemolyzing red blood cells is 30 g / dL to 50 g / dL. By diluting the hemoglobin solution with an aqueous solvent such as physiological saline and then encapsulating it in a capsule, the hemoglobin concentration of the hemoglobin aqueous solution encapsulated in the capsule can be set to 10 g / dL to 45 g / dL. This hemoglobin concentration corresponds to 1.6 mM to 7.0 mM when converted to a molar concentration. The molar concentration is calculated based on the molecular weight of hemoglobin being 64,500. One molecule of hemoglobin is composed of four globin polypeptides, so the amount of oxygen or carbon monoxide that binds to one mole of hemoglobin is four times that amount, or four moles.
[0061] The aqueous solution of the colloid in which the encapsulated hemoglobin is dispersed can provide the dispersion of the encapsulated hemoglobin with a colloid osmotic pressure. The colloid includes, but is not limited to, albumin (5 g / dL or less), hydroxyethyl starch (10 g / dL or less), dextran (10 g / dL or less), and modified gelatin (5 g / dL or less). The crystalloid osmotic pressure is preferably adjusted to 300 mOsm.
[0062] As described above, when the photosensitizer of the present invention is administered intravenously, the photosensitizer administered intravenously reaches the capillaries of the subject to be treated via the heart and arteries, so a large amount of the photosensitizer needs to be administered. The amount reaches 5% to 20% of the circulating blood volume. If the circulating blood volume is about 1 / 13 of the patient's body weight, for example, in a child weighing 20 kg, the circulating blood volume is about 1.5 kg, or about 1.5 L, so 5% to 20% of the circulating blood volume corresponds to about 77 mL to 307 mL. In other words, the amount of the photosensitizer administered per kg of the patient's body weight is 3.85 mL to 15.35 mL. Therefore, the dose of the photosensitizer of the present invention is ultimately determined by the doctor who performs the treatment, but generally, in the case of intravenous administration, it can be 2 mL to 25 mL or 3.85 mL to 15.35 mL per kg of the patient's body weight.
[0063] One embodiment of the present invention is a photosensitizer for laser radiation therapy therapeutically targeting blood vessels, wherein the capsule is a liposome, a polymersome or a polymeric thin film.
[0064] When the capsule of the encapsulated hemoglobin of the present invention is a polymersome, the polymersome is a capsule formed by an amphiphilic polymer in which a hydrophilic polymer and a hydrophobic polymer are copolymerized, for example, an amphiphilic diblock copolymer of polybutadiene-polyethylene oxide (PBD-PEO).
[0065] When the capsule of the encapsulated hemoglobin of the present invention is a thin polymer film, the thin polymer film can be made of polymers including, but not limited to, polystyrene, gum arabic, nylon, silicone, and other polymers, bio-derived materials such as gelatin, copolymers of poly-ε-caprolactam or polyethylene glycol with biodegradable polymers such as polylactic acid or polyglycolic acid, polysaccharides, and copolymers of amino acid polymers.
[0066] One embodiment of the present invention is a photosensitizer for laser irradiation therapy targeting blood vessels, the liposome containing a phosphatidylcholine-type phospholipid, cholesterol, a negatively charged lipid, and a lipid bound with polyethylene glycol, wherein the phosphatidylcholine-type phospholipid is 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine, the negatively charged lipid is 1,5-O-dihexadecyl-N-succinyl-L-glutamate, and the lipid bound with polyethylene glycol is 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-Poly(oxyethylene) 5000(molecular weight of polyethylene glycol chain: 5000). Here, the particle size of the liposome is controlled so that the vesicle encapsulating the high-concentration Hb solution can easily pass through the capillaries, and the dispersion stability in the blood is improved. The liposome may be a vesicle of a phospholipid bilayer membrane of any structure that encapsulates an aqueous hemoglobin solution and allows the liposome to be suspended in the aqueous solution. The liposome may be a vesicle made of a single phospholipid bilayer membrane.
[0067] In the phosphatidylcholine type phospholipid, the fatty acid ester-bonded to the 1,2-hydroxyl group at the 1st and 2nd positions of the glycerol backbone is preferably saturated in order to suppress the generation of lipid peroxides. In addition to 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC), 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphatidylcholine (PMPC), 1-stearo ... (SMPC), hydrogenated lecithin derived from soybeans (HSPC), and unsaturated phospholipids with oleic acid, a relatively stable fatty acid, bound thereto, such as 1-stearoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (SOPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC) are preferred. Among these phospholipids, DPPC has been considered to be preferred in consideration of the stability of the resulting endoplasmic reticulum and the avoidance of accumulation after capture by macrophages. However, from the viewpoint of ease of production, phosphatidylcholine-type phospholipids with a phase transition temperature lower than that of DPPC (Tc = 41 ° C.) are preferred in terms of dispersibility and control of particle size, such as SMPC (Tc = 30 ° C.), PMPC (28 ° C.), DMPC (23 ° C.), SOPC (6 ° C.), and POPC (-3 ° C.). In the past, phosphatidylcholine-type lipids with low phase transition temperatures were considered to have unstable structures of the resulting vesicles, but it is necessary to determine whether the stability is sufficient from the perspective of practical applications.
[0068] As the negatively charged lipid, 1,5-O-dihexadecyl-N-succinyl-L-glutamate (DHSG) is preferably used. The negatively charged lipid is necessary to reduce the number of coating layers (lamellarity) of the liposome and to impart biocompatibility.
[0069] Cholesterol (CHO) eliminates the clear phase transition temperature of phosphatidylcholine-type phospholipids and stabilizes lipid membranes.
[0070] The liposome may be modified with polyalkylene glycol, typically polyethylene glycol (PEG-modified), for the purpose of improving blood retention, inhibiting aggregation between hemoglobin vesicle particles, improving dispersion stability, etc. The PEG-modification of liposomes can be performed by a general method, for example, by preparing liposomes using a suitable lipid bound to PEG as a constituent lipid of the lipid bilayer. In the case of the liposomes of the present invention, the PEG-modification is preferably performed by using 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine (DSPE) bound to PEG (PEG-DSPE) as a constituent lipid of the lipid bilayer. The molecular weight of the polyethylene glycol is about 400 Da to 12000 Da, preferably 1000 Da to 5000 Da. As the PEG-modified lipid, 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-Poly(oxyethylene) having a molecular weight of 5000 in the polyethylene glycol chain is preferably used. 5000 It is preferable to use (PEG-DSPE). In relation to the PEG modification, as an alternative material to PEG, which is widely used as a medical polymer, the surface of the liposome may be modified using a substance in which a polymer such as poly(2-oxazoline) or polysarcosine is bound to a lipid such as DSPE.
[0071] An example of a preferred lipid constituting the lipid bilayer membrane of the liposome of the present invention is DPPC, CHO, DHSG and PEG-DSPE, the molar ratio of which is 5:4:0.9:0.03.
[0072] One embodiment of the present invention is a photosensitizer for laser irradiation therapy targeting blood vessels, comprising COHb as an aqueous solution of a noncellular hemoglobin-derived oxygen carrier bound to CO. Here, the noncellular hemoglobin-derived oxygen carrier is at least one selected from the group consisting of polymerized modified hemoglobin, water-soluble polymer-bound modified hemoglobin, and intramolecularly crosslinked hemoglobin.
[0073] The non-cellular hemoglobin-derived oxygen carriers are described in detail in Taguchi, K. et al. (J. Funct. Biomater. 8, 11 (2017)) and Chang TM (Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2:418-30 (2010)).
[0074] One embodiment of the present invention is a photosensitizer for laser irradiation therapy targeting blood vessels as a therapeutic target, wherein the noncellular hemoglobin-derived oxygen carrier is polymerized modified hemoglobin and / or water-soluble polymer-bound modified hemoglobin.
[0075] The polymerized modified hemoglobin includes, but is not limited to, hemoglobin polymers bound to lysine residues on the surface of hemoglobin with a crosslinking agent such as glutaraldehyde (Gould SA et al., J. Am. Coll. Surg., 195:445-52 (2002)), and Hb polymers in which the terminal carboxylic acid of the globin chain of Hb is directly bound to a lysine residue via an intermolecular bond (Matheson B. et al., J. Appl. Physiol., 93:1479-86 (2002)), to which carbon monoxide is bound.
[0076] The water-soluble polymer-bound modified hemoglobin includes, but is not limited to, a copolymer of hemoglobin and hydroxyethyl starch (Hu T. et al., Biochem. J., 392:555-64(2005)) and a PEG-bound hemoglobin in which polyethylene glycol (PEG) having a methoxy group at one end is bound to the surface of hemoglobin (Chang, TM, Appl. Biochem. Biotechnol., 10:5-24(1984)), to which carbon monoxide is bound.
[0077] One embodiment of the present invention is a photosensitizer for laser irradiation therapy targeting blood vessels, administered at a hemoglobin concentration of 0.46 mM to 3.6 mM, where the hemoglobin concentration of 0.46 mM to 3.6 mM (3 g / dL to 23 g / dL) is the concentration of hemoglobin in the total volume of the photosensitizer formulation of the present invention, in which COHb is dispersed in an aqueous solvent containing electrolytes, carbohydrates, amino acids, and / or colloids, regardless of whether it is encapsulated or not.
[0078] When the photosensitizer is an aqueous solution of a noncellular hemoglobin-derived oxygen carrier bound to CO, the molar concentration of hemoglobin in the total volume of the photosensitizer formulation of the present invention refers to the molar concentration when all of the hemoglobin contained in the hemoglobin polymer or copolymer in the noncellular hemoglobin-derived oxygen carrier is converted into hemoglobin monomer.
[0079] One embodiment of the present invention is a photosensitizer for laser radiation therapy, administered in an amount of 0.004 to 0.36 mmol (millimoles) of carbon monoxide per kg of body weight, with blood vessels as the therapeutic target.
[0080] Since almost all of the CO is administered bound to hemoglobin, the total amount of CO administered can be easily managed. The hemoglobin contained in the photosensitizer preparation of the present invention contains COHb, which has a vasodilatory effect, and after administration, it gradually releases CO gas and is converted to O2Hb. COHb also exhibits the same light absorption as O2Hb and can also enhance laser irradiation therapy. Furthermore, COHb is photodissociated by laser irradiation in the visible light range to release CO, which can locally increase the CO concentration. Since CO gas is also toxic, hemodynamics and blood gas composition are continuously monitored during administration. In addition, since CO dissociated from the administered COHb only ultimately is exhaled as exhaled air after exerting a pharmacological effect in the body, it is important to maintain and manage the respiratory condition. The transition of the amount of COHb in the blood can be easily calculated from the absorbance ratio to deoxyHb at the Soret band or Q band in the visible absorption spectrum of the collected blood. The dosage of the photosensitizer preparation of the present invention is an amount equivalent to 0.004 mmol to 0.36 mmol of CO per kg of body weight.
[0081] The active ingredient COHb contained in the photosensitizer for laser irradiation therapy targeting blood vessels of the present invention is replaced from O2Hb for the purpose of making hemoglobin heat-resistant before the hemoglobin solution purified and concentrated from blood is subjected to heat treatment for virus inactivation. Therefore, in the photosensitizer of the present invention, the active ingredient COHb is about 100% or at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 97% of the hemoglobin contained in the photosensitizer of the present invention. Therefore, when the photosensitizer of the present invention is administered at a hemoglobin concentration of 0.46 mM to 3.6 mM (3 g / dL to 23 g / dL), the weight percentage of the active ingredient COHb in the entire preparation of the photosensitizer of the present invention is about 3% to about 23% when about 100% of Hb is COHb. The weight percentage of COHb, an active ingredient in the entire photosensitizer preparation of the present invention, is about 1.95% to about 14.95% when at least 65% of Hb is COHb. That is, the weight percentage of COHb, an active ingredient in the entire photosensitizer preparation of the present invention, is within the range of about 1.95% to about 23%.
[0082] One embodiment of the present invention is a photosensitizer for laser irradiation therapy targeting blood vessels for the treatment of at least one disease selected from the group consisting of simple hemangiomas, capillary malformations, salmon patches, Unna's nevus, hemangiomas, port wine stains, Sturgey-Weber syndrome, Klippel-Trenaunay-Weber syndrome and other skin lesions caused by capillary hyperplasia, rosacea and telangiectasias, pathological vascular dilation associated with hypertrophic scars, traumatic scars and post-skin graft scars, strawberry hemangiomas and infantile hemangiomas of the skin, and tufted hemangiomas, telangiectatic granulomas and other vascular neoplastic lesions of the skin.
[0083] The photosensitizer of the present invention absorbs photons irradiated by a dye laser with the absorption wavelength of COHb and releases CO, which dilates blood vessels and increases the flow rate of COHb-V and red blood cells. After releasing CO, Hb absorbs the irradiated photons and converts them into thermal energy, which is transmitted to the vascular wall and destroys the vascular endothelium. On the other hand, the released CO not only dilates blood vessels, but also exerts an anti-inflammatory effect on perivascular tissues. Therefore, the photosensitizer of the present invention suppresses inflammation associated with burns of perivascular tissues caused by laser irradiation, reduces damage to perivascular tissues, and simultaneously causes abnormal blood vessels to be necrotized and absorbed. As a result, compared with conventional laser irradiation therapy that targets blood vessels, the effect on blood vessels is higher but the side effects on perivascular tissues are fewer. Therefore, the disease to which the photosensitizer of the present invention can be applied is a disease caused by hyperplasia of capillaries on the body surface. The body surface refers to a depth of 150 to 400 μm from the skin surface, which is reachable by laser light.
[0084] The diseases caused by capillary hyperplasia on the body surface specifically include, but are not limited to, simple hemangioma, capillary malformation, salmon patch, Unna nevus, hemangioma, port wine stain, Sturgey-Weber syndrome, and Klippel-Trenaunay-Weber syndrome, which are pink, red, or purple flat skin lesions caused by capillary hyperplasia that appear at birth or during the neonatal period, telangiectasia including rosacea, pathological vascular dilation associated with hypertrophic scars, traumatic scars, and post-skin graft scars, strawberry hemangioma and infantile hemangioma of the skin, and other vascular tumor lesions of the skin including tufted hemangioma and vascular granuloma. The diseases to which the photosensitizer of the present invention can be applied are preferably simple hemangioma, capillary malformation, salmon patch, hemangioma, and / or port wine stain.
[0085] One embodiment of the present invention is the use of COHb for the manufacture of a photosensitizer for laser radiation therapy that therapeutically targets blood vessels.
[0086] The photosensitizer of the present invention can be used for the treatment of at least one disease selected from the group consisting of simple hemangioma, capillary malformation, salmon patch, Unna's nevus, hemangioma, port wine stain, Sturgey-Weber syndrome, Klippel-Trenaunay-Weber syndrome and other skin lesions caused by capillary hyperplasia, rosacea and telangiectasia, pathological vascular dilation associated with hypertrophic scars, traumatic scars and post-skin graft scars, strawberry hemangioma and infantile hemangioma of the skin, and tufted hemangioma, telangiectatic granuloma and other vascular tumor lesions of the skin.
[0087] One embodiment of the present invention is a method for treating at least one disease selected from the group consisting of simple hemangiomas, capillary malformations, salmon patches, Unna's nevus, hemangiomas, port wine stains, Sturgey-Weber syndrome, Klippel-Trenaunay-Weber syndrome, and other skin lesions caused by capillary hyperplasia, rosacea and telangiectasias, pathological vascular dilation associated with hypertrophic scars, traumatic scars, and post-skin graft scars, strawberry hemangiomas and infantile hemangiomas of the skin, and vascular neoplastic lesions of the skin, including tufted hemangiomas, telangiectatic granulomas, and other cutaneous vascular neoplastic lesions, comprising administering a photosensitizer of the present invention into a blood vessel and irradiating the blood vessel to be treated with a laser as a therapeutic target.
[0088] In this specification, the conjunction "about" used to modify a numerical value means a numerical range of 90% or more and 110% or less of the numerical value. For example, when the average size of COHb-C is "about 250 nm," the average size of COHb-C is a numerical value within a numerical range including the lower and upper limits of 225 nm and 275 nm, respectively.
[0089] All documents mentioned herein are incorporated by reference in their entirety.
[0090] The following examples of the present invention are for illustrative purposes only and do not limit the technical scope of the present invention. The technical scope of the present invention is limited only by the claims. The present invention can be modified, for example, by adding, deleting, and replacing the constituent elements of the present invention, without departing from the spirit of the present invention. EXAMPLES
[0091] Example 1 Preparation of the photosensitizer for dye laser treatment of the present invention The hemoglobin vesicles contained in the dye laser treatment photosensitizer of the present invention were prepared according to a previous report (Sakai H. et al., J. Pharmacol. Exp. Ther., 2004; 311:874-84). First, an equal amount of physiological saline was added to human red blood cells, and the procedure of centrifuging and removing the supernatant was repeated three times to obtain washed red blood cells. Distilled water for injection was added to the red blood cells to cause hemolysis, and ultrafiltration membrane processing was performed to obtain a stroma-free hemoglobin solution. Carbon monoxide was bound to the stroma-free hemoglobin solution, which was then heated at 60°C for 10 hours, and further ultrafiltration membrane processing was performed to obtain a high-purity, high-concentration Hb solution (40 g / dL). Pyridoxal 5'-phosphate was added to the solution as an allosteric factor in an equimolar amount relative to hemoglobin. Next, a mixed lipid powder (dipalmitoylphosphatidylcholine / cholesterol / negatively charged lipid / polyethylene glycol-bound distearoylphosphatidylethanolamine) was added, and hemoglobin vesicles were formed by the kneading method described in International Publication No. WO2012 / 137834, and the average particle size was controlled to 250 nm. Hemoglobin that was not encapsulated in the liposomes was removed by an ultrafiltration membrane, and the hemoglobin concentration was adjusted to 10 g / dL to prepare COHb-V. In addition, COHb-V was irradiated with visible light under an oxygen stream to photodissociate the carbon monoxide bound to Hb and replace it with oxygen. Finally, the mixture was sealed in a glass container, and nitrogen gas was passed through to completely remove oxygen and then stored. In the following examples, the hemoglobin vesicles from which oxygen had been completely removed are referred to as "Hb-V".
[0092] Example 2: Effect of photosensitizers on dye laser irradiation of rabbit ears The following animal experiments were performed in accordance with the experimental protocol approved in accordance with the Chiba University Animal Experiment Implementation Regulations (Animal Experiment Protocol Approval Number: Animal 1-98).
[0093] Three 20-week-old rabbits (Slc:JW / CSK, male, Japan SLC) were anesthetized by inhalation and 10 to 15 minutes later, four locations on the left auricle were irradiated with a variable long-pulse dye laser. Approximately 15 minutes after the laser irradiation to the left auricle, 10 mL of hemoglobin vesicle Hb-V or COHb-V, or a mixture of 5 mL of Hb-V and 5 mL of COHb-V (hereinafter referred to as "Mixed") was intravenously administered to each rabbit. Approximately 30 minutes after the administration of hemoglobin vesicle, four locations on the right auricle of each rabbit were irradiated with a variable long-pulse dye laser. The variable long-pulse dye laser used was Vbeam (registered trademark) manufactured by Candela Corp (Wayland, Massachusetts, USA). The irradiation conditions were a circular irradiation area with a diameter of 7 mm, an irradiation pulse width of 1.5 ms, and an irradiation energy of 10 J / cm. 2 The irradiated skin surface was cooled with a cryogen for 20 ms before irradiation (dynamic cooling device). A variable long-pulse dye laser was irradiated at four locations on the auricle of each individual. Irradiation sites 1 to 4 were numbered in order from the most proximal irradiated site on the auricle to irradiation site 1, and the most distal irradiated site was irradiated site 4. Four days after irradiation, the external surface of the auricle skin in the irradiated area was observed and photographed, and tissue from the irradiated area was collected and fixed in formalin to prepare a paraffin-embedded HE-stained specimen. Five tissue sections were prepared in succession from each irradiated site, for a total of 120 sections.
[0094] Histological findings of the auricular artery and vein were defined as degeneration / necrosis of the vascular wall. Changes in perivascular tissues were focused on edema, hemorrhage, necrosis of collagen fiber bundles, and inflammatory cell infiltration. Each finding was evaluated based on the definitions shown below. Inflammatory cell infiltration was evaluated on a 5-point scale from - to 3+, using the number and distribution degree per visual field as indicators. Other findings were also recorded if observed.
[0095] Degeneration and necrosis of blood vessel walls -:no change ±: Partial degeneration and necrosis of endothelial cells +: Endothelial cell loss 2+: Endothelial cell loss, degeneration and necrosis of the tunica media and adventitia (remaining cellular components) 3+: Loss of endothelial cells, degeneration and necrosis of the tunica media and adventitia (loss of cellular components)
[0096] Perivascular tissue edema -:no change ±: Slightly visible around blood vessels +: Slightly widespread from blood vessels to the epidermis 2+: Diffuse, mainly in blood vessels 3+: Observed throughout the irradiated area (tissue section)
[0097] Hemorrhage in perivascular tissues -:no change ±: slight leakage around blood vessels including small blood vessels +: Scattered around blood vessels and in the dermis 2+: Scattered or clustered foci are observed around blood vessels and in the dermis layer. 3+: Widespread
[0098] Collagen fiber bundle necrosis -:no change ±: slight perivascular coagulation necrosis +: Coagulation or lysis necrosis spreading from around blood vessels 2+: Diffuse coagulation or lysis necrosis 3+: General coagulation or fusion necrosis of the irradiated area (tissue section)
[0099] Analyzing data The graded histological findings were tested for significance using the Mann-Whitney U test, and the total positive grades were tested for significance using a one-sided Fisher's exact probability test between Hb-V or COHb-V administration and non-administration, and between Hb-V administration and COHb-V administration (significance level: 5%).
[0100] Test results (1) Hb-V administration The findings are shown in Table 1 below.
[0101] [Table 1]
[0102] In Table 1, Hb-V(-) means the site where laser irradiation was performed before Hb-V administration (non-administered) in an individual administered with Hb-V, and Hb-V(+) means the site where laser irradiation was performed after Hb-V administration (administered) in an individual administered with Hb-V.
[0103] Four of the 20 untreated ear tissues and two of the 20 Hb-V-treated ear tissues did not have an auricular artery on the tissue sections, so these could not be evaluated. Degeneration and necrosis of the vascular wall was observed in the auricular artery of all specimens except the above six, and in the auricular veins of all specimens, and the degree of degeneration and necrosis of the auricular vein was significantly increased in the Hb-V-treated specimens compared to the untreated specimens. In the surrounding tissues, inflammatory cell infiltration, edema, hemorrhage, and necrosis of collagen fiber bundles were observed in both the untreated and Hb-V-treated specimens, but the frequency of inflammatory cell infiltration and the degree of edema and necrosis of collagen fiber bundles were significantly reduced in the Hb-V-treated specimens.
[0104] Test Results (2) COHb-V Administration The findings are shown in Table 2 below.
[0105] [Table 2]
[0106] In Table 2, COHb-V(-) means the site where laser irradiation was performed (non-administered) before COHb-V administration in an individual administered COHb-V, and COHb-V(+) means the site where laser irradiation was performed (administered) after COHb-V administration in an individual administered COHb-V.
[0107] In all specimens, both untreated and COHb-V-treated, mild or moderate degeneration and necrosis of the vascular wall was observed in both the auricular artery and auricular vein, but there was no difference in frequency or severity between untreated and COHb-V-treated specimens. On the other hand, in the surrounding tissues, the frequency and severity of inflammatory cell infiltration, edema, hemorrhage, and necrosis of collagen fiber bundles were significantly reduced with COHb-V administration.
[0108] Test Results (3) Comparison of histological changes between Hb-V-administered and COHb-V-administered individuals The findings are shown in Table 3 below.
[0109] [Table 3]
[0110] In Table 3, Hb-V(+) means the site where laser irradiation was performed after Hb-V administration in an individual administered Hb-V, and COHb-V(+) means the site where laser irradiation was performed after COHb-V administration in an individual administered COHb-V.
[0111] No difference in frequency or severity of degeneration and necrosis of the vascular wall was observed between Hb-V and COHb-V administration in the auricular artery, but the severity of findings was aggravated by COHb-V administration in the auricular vein. In the surrounding tissues, the frequency and severity of edema, hemorrhage, and necrosis of collagen fiber bundles were significantly reduced by COHb-V administration.
[0112] Test results (4) Comparison of histological changes between subjects administered equal amounts of Hb-V and COHb-V (hereinafter referred to as "Mixed") and subjects administered COHb-V The findings are shown in Table 4 below.
[0113] [Table 4]
[0114] In Table 4, Mixed(+) refers to the site where laser irradiation was performed after administration of equal amounts of Hb-V and COHb-V in an individual, and COHb-V(+) refers to the site where laser irradiation was performed after administration of COHb-V in an individual.
[0115] No difference in frequency or severity of degeneration and necrosis of the vascular wall was observed between Mixed and COHb-V administration in the auricular artery, but the severity of degeneration and necrosis of the vascular wall was enhanced by COHb-V administration in the auricular vein. In the surrounding tissues, the frequency and severity of edema, hemorrhage, and necrosis of collagen fiber bundles were significantly reduced by COHb-V administration.
[0116] From the above pathological and statistical results, Hb-V, COHb-V and Mixed administration all caused less damage to perivascular tissues than non-administration, and COHb-V administration caused even less damage than Hb-V and Mixed administration. In addition, when comparing the degree of venous damage with COHb-V administration, Hb-V and Mixed administration, COHb-V administration caused more severe damage. COHb-V, which causes strong thermal damage to blood vessels while at the same time reducing the thermal effect on tissues other than blood vessels, is superior to Hb-V as a photosensitizer for laser irradiation therapy targeting blood vessels as a therapeutic target.
[0117] Test results (5) External findings of the ear skin at the irradiated area Figures 1-A, 2-A, 3-A, and 4-A are photographs of the external surface of the ear skin at irradiated sites 1, 2, 3, and 4, respectively, four days after the ear of a rabbit administered Hb-V was irradiated with a dye laser. Figures 1-B, 2-B, 3-B, and 4-B are photographs of the external surface of the ear skin at irradiated sites 1, 2, 3, and 4, respectively, four days after the ear of a rabbit administered COHb-V was irradiated with a dye laser. The black rings in the figures are marks for the irradiation range written on the ear skin with a felt pen. The white rings in the figures were attached to the photographs to indicate the position of the blood vessel in the center of the irradiation site in the photograph. The arrows in Figures 1-B, 2-B, 3-B, and 4-B indicate the positions of blood vessels that were narrowed or blocked by irradiation.
[0118] Comparing Figures 1-A, 2-A, 3-A, and 4-A, it was found that the degree of purpura and redness of the skin tended to decrease in the order from irradiation site 1 to irradiation site 4. A similar tendency was observed in comparing Figures 1-B, 2-B, 3-B, and 4-B. However, when comparing the same irradiated sites, i.e., Figure 1-A vs. 1-B, Figure 2-A vs. 2-B, Figure 3-A vs. 3-B, and Figure 4-A vs. 4-B, the rabbits administered COHb-V (Figures 1-B, 2-B, 3-B, and 4-B) had less severe purpura and redness of the skin than the rabbits administered Hb-V (Figures 1-A, 2-A, 3-A, and 4-A), but the blood vessels had narrowed, and vascular stenosis or occlusion was observed, as indicated by the arrows in Figures 1-B, 2-B, 3-B, and 4-B.
[0119] The findings on the surface of the ear skin at the irradiated site in this test support the effect of the photosensitizer of the present invention, which has a greater effect on blood vessels but less side effects on perivascular tissues.
[0120] It is known that CO gas dissociated from COHb dilates blood vessels and exhibits anti-inflammatory effects. However, the quantum yield of photodissociation of COHb contained in the photosensitizer of the present invention is extremely high at 0.5 to 1, and the laser light is also extremely strong, so in laser irradiation therapy using the photosensitizer of the present invention, it is thought that almost all of the CO bound to COHb in the blood vessels at the irradiation site will dissociate at the same time. As a result, an extremely high concentration of CO is generated locally at the irradiation site, and the vasodilatory effect and the anti-inflammatory effect in the tissues surrounding the blood vessels are enhanced, so that the damage effect on the blood vessel wall is large, but the side effects on the skin at the irradiation site are suppressed. As described above, the examples of this specification have proven that the photosensitizer of the present invention enhances the therapeutic effect of laser irradiation therapy targeting blood vessels. [Industrial Applicability]
[0121] According to the present invention, by generating an extremely high concentration of CO locally at the irradiation site, blood vessels can be dilated and the anti-inflammatory effect in the tissues surrounding the blood vessels can be enhanced, so that the therapeutic effect of laser irradiation therapy targeting blood vessels can be enhanced. Therefore, the present invention is extremely useful as a clinical treatment method using laser irradiation therapy targeting blood vessels.
Claims
1. A photosensitizer for laser irradiation therapy that contains carbon monoxide (CO)-bound hemoglobin (hereinafter referred to as "COHb") and targets blood vessels.
2. The photosensitizer according to claim 1 , comprising the COHb as encapsulated hemoglobin in which an aqueous COHb solution is encapsulated.
3. The photosensitizer according to claim 2, wherein the aqueous solution contains pyridoxal 5'-phosphate.
4. 4. The photosensitizer according to claim 2 or 3, which has substantially no enzyme activity to reduce methemoglobin.
5. The photosensitizer according to claim 4 , wherein the aqueous solution contains NADH and / or NADPH.
6. The photosensitizer according to claim 2 , wherein the aqueous solution contains a biodegradable fluorescent dye.
7. 7. The photosensitizer according to claim 2, wherein the concentration of hemoglobin in the aqueous solution is 1.6 mM to 7.0 mM.
8. The photosensitizer according to claim 2 , wherein the capsule is a liposome, a polymersome or a thin polymer film.
9. The liposome is composed of 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine, which is a phosphatidylcholine type phospholipid, cholesterol, 1,5-O-dihexadecyl-N-succinyl-glutamate, which is a negatively charged lipid, and 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-poly(oxyethylene), which is a lipid bound with polyethylene glycol. 5000 The photosensitizer according to claim 8 , comprising: (molecular weight of polyethylene glycol chain: 5,000).
10. The photosensitizer according to claim 1, comprising COHb as an aqueous solution of a non-cellular hemoglobin-derived oxygen carrier bound to CO, the COHb being at least one non-cellular hemoglobin-derived oxygen carrier selected from the group consisting of polymerized modified hemoglobin, water-soluble polymer-bound modified hemoglobin, and intramolecularly crosslinked hemoglobin.
11. The photosensitizer according to claim 10 , wherein the non-cellular hemoglobin-derived oxygen carrier is a polymerized modified hemoglobin and / or a water-soluble polymer-bound modified hemoglobin.
12. 12. The photosensitizer of any one of claims 1 to 11, which is administered at a hemoglobin concentration of 0.46 mM to 3.6 mM.
13. The photosensitizer according to any one of claims 1 to 12, wherein 0.004 mmol (millimoles) to 0.36 mmol (millimoles) of carbon monoxide is administered per kg of body weight.
14. The photosensitizer according to any one of claims 1 to 13 for the treatment of at least one disease selected from the group consisting of simple hemangioma, capillary malformation, salmon patch, Unna's nevus, hemangioma, port wine stain, Sturgey-Weber syndrome, Klippel-Trenaunay-Weber syndrome and other skin lesions caused by capillary hyperplasia, rosacea and telangiectasia, pathological vascular dilation associated with hypertrophic scars, traumatic scars and post-skin graft scars, strawberry hemangioma and infantile hemangioma of the skin, and tufted hemangioma, telangiectatic granuloma and other vascular tumor lesions of the skin.
Citation Information
Patent Citations
Ligand replacement type transfusion preparation
JP2007269665A
Method for producing endoplasmic reticulum
WO2012137834A1
